Recent studies show that FXR functions as a tumor/metastasis suppressor in intrahepatic CCA (iCCA), in part 1by inhibiting the IL-6/STAT3 signaling axis and epithelial-mesenchymal transition (EMT); activation of FXR by the agonist Obeticholic Acid (OCA) reduces CCA carcinogenic potential in preclinical models, dampens proliferative signaling (49, 50), and modifies the immune microenvironment by promoting dendritic cell antigen-presentation and reducing myeloid-derived suppressor cell (MDSC) infiltration. Here, IL6 is linked to cholangiocarcinoma.